Sugi Predict

Sugi Predict / Compounds / SCHEMBL2724465

SCHEMBL2724465

SCHEMBL2724465

CC(C)(C)OC(=O)NCC1(Nc2nc(Cl)ncc2Br)CCCCC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ STK17B O94768 1/20 0.47
▸ STK17A Q9UEE5 1/20 0.47
▸ P2RX7 Q99572 1/20 0.40
▸ NPFFR1 Q9GZQ6 1/20 0.38
▸ NPFFR2 Q9Y5X5 1/20 0.38
▸ FPR3 P25089 5/20 0.35
▸ FPR2 P25090 5/20 0.35
▸ IGF1R P08069 1/20 0.35
▸ MAPKAPK2 P49137 1/20 0.34
▸ DRD2 P14416 5/20 0.33
▸ MEN1 O00255 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMO Q99835 1/20 0.32
▸ CPB2 Q96IY4 1/20 0.31
▸ SYK P43405 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2726118 0.99 STK17B (0.48) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL20980140 0.88 STK17B (0.47) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL20926997 0.88 STK17B (0.47) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL18637987 0.88 P2RX7 (0.37) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL22995049 0.86 STK17B (0.46) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL21967075 0.84 KMT2A (0.34) P2RX7MEN1KMT2A
SCHEMBL4549915 0.84 STK17B (0.44) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL20959511 0.83 STK17B (0.43) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL30990398 0.83 STK17B (0.43) STK17BSTK17AP2RX7NPFFR1NPFFR2
SCHEMBL21967065 0.82 MEN1 (0.34) STK17BSTK17AP2RX7MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 227 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115536663-A Triracil intermediate and preparation and application thereof 杭州科巢生物科技有限公司 2022-12-30 — — CN claimed
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 — — EP disclosed
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors PHARMACOSMOS HOLDING A/S (DK) 2025-04-29 — — US disclosed
EP-2968291-B1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION PHARMACOSMOS HOLDING AS (DK) 2025-04-16 — — EP disclosed
US-20240109906-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY G1 THERAPEUTICS, INC. (US) 2023-11-30 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION G1 THERAPEUTICS, INC. (US) 2023-11-16 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237533-A1 CDK Inhibitors G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237544-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
US-20130237534-A1 CDK INHIBITORS G1 THERAPEUTICS, INC. (US) 2013-09-12 — — US disclosed
EP-2632467-A1 CDK INHIBITORS G1 Therapeutics, Inc. (US) 2013-09-04 — — EP disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed
WO-2012061156-A1 CDK INHIBITORS TAVARES FRANCIS X (US) 2012-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237534-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885P2RX7 4577/4885
US-20240109906-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885P2RX7 4577/4885
US-20230364098-A1 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION RB1, CDK4, CDKN1A STK17B 986/4885STK17A 957/4885P2RX7 3653/4885
US-12285431-B2 Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors RB1, CDK4, CDK6 STK17B 852/4885STK17A 1072/4885P2RX7 4438/4885
US-20230381189-A1 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY CDK6, CCNC, MCL1 STK17B 1245/4885STK17A 1696/4885P2RX7 4351/4885
US-20130237533-A1 CDK Inhibitors CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885P2RX7 4577/4885
US-20130237544-A1 CDK INHIBITORS CDK3, CDK9, CDK6 STK17B 149/4885STK17A 152/4885P2RX7 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.